Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 222Genitourinary 5Thoracic 1NET 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 14Neoplasms 5Adenocarcinoma of Lung 4Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Mesothelioma 2Colorectal Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 24Nivolumab 19atezolizumab 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7durvalumab 5Ipilimumab 5fludarabine 4Trastuzumab 4cemiplimab 3cabozantinib 3avelumab 3Sunitinib 3Biopsy 3ulixertinib 2toripalimab 2tislelizumab 2spartalizumab 2sargramostim 2relatlimab 2palbociclib 2lenvatinib 2epacadostat 2enzalutamide 2cyclopropapyrroloindole 2copanlisib 2budigalimab 2aldesleukin 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Sorafenib × Thoracic × Clear all
NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡